Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Tonix Pharmaceuticals Holding (TNXP) Receivables - Other (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Receivables - Other data on record, last reported at $1.7 million in Q3 2025.

  • For Q3 2025, Receivables - Other fell 21.87% year-over-year to $1.7 million; the TTM value through Sep 2025 reached $1.7 million, down 21.87%, while the annual FY2024 figure was $881000.0, 340.5% up from the prior year.
  • Receivables - Other reached $1.7 million in Q3 2025 per TNXP's latest filing, down from $1.9 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $4.6 million in Q4 2023 and bottomed at $226000.0 in Q1 2025.
  • Average Receivables - Other over 3 years is $1.6 million, with a median of $1.6 million recorded in 2023.
  • The widest YoY moves for Receivables - Other: up 181.66% in 2024, down 80.81% in 2024.
  • A 3-year view of Receivables - Other shows it stood at $4.6 million in 2023, then plummeted by 80.81% to $881000.0 in 2024, then surged by 89.33% to $1.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables - Other were $1.7 million in Q3 2025, $1.9 million in Q2 2025, and $226000.0 in Q1 2025.